Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Now watching

Next video starts in : 7 Play

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People
Replay video
Up next

Amazon is in Talks to Buy Luxury Online Retailer Net-A-Porter

Unlock your personal NFL Now stream by signing in to NFL.com

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

by TheStreet 1:02 mins

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

by TheStreet 1:02 mins

New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York.

TheStreet

We The Economy

  1. 6:40

    cave-o-nomics

  2. 7:38

    Supply & Dance, Man!

  3. 5:26

    GDP SMACKDOWN

  4. Lemonade War

  5. 6:55

    A BEE’S INVOICE; THE HIDDEN VALUE IN NATURE

  6. 7:06

    Fed Head